Lv31
296 积分 2023-12-14 加入
Prostate cancer
5小时前
已完结
Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide
29天前
已关闭
EZH2 accompanies prostate cancer progression
1个月前
已完结
Targeting EZH2 with tazemetostat
1个月前
已完结
Prostate cancer
1个月前
已关闭
Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients
2个月前
已完结
Management of apalutamide‐induced rash with focus on early peaks
2个月前
已完结
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
2个月前
已关闭
Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review
2个月前
已完结
Prostate Cancer
2个月前
已完结
皖公网安备34019202002308
